@prefix this: . @prefix sub: . @prefix schema: . @prefix np: . @prefix dct: . @prefix rdf: . @prefix nt: . @prefix xsd: . @prefix rdfs: . @prefix orcid: . @prefix bl: . @prefix prov: . @prefix npx: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { bl:category bl:Disease . sub:association rdf:object ; rdf:predicate bl:treats; rdf:subject ; a rdf:Statement; rdfs:label "votrient r votrient is indicated for the treatment of patients with advanced soft tissue sarcoma sts who have received prior chemotherapy limitation s of use votrient is a kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma 1 advanced soft tissue sarcoma who have received prior chemotherapy 1 limitation s of use"; bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation; bl:provided_by ; bl:relation schema:TreatmentIndication . bl:category bl:Drug . } sub:provenance { sub:assertion prov:wasAttributedTo orcid:0000-0002-1468-3557 . } sub:pubinfo { sub:sig npx:hasAlgorithm "RSA"; npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB"; npx:hasSignature "N0mp/1ASlHf6sKsxamj20OzxZfUM6X80sUMWlHMHkjBmFqwOYPEUbrkskCGwQ5MRr/Y2fgEKOUu9PdGH4ftvFfr+cTAon0eEGOka/tPWowLvNGpVZlsjMi/UwiVf0GJXYELaioA9O8ulQqIoFjzLlIVsvvcgtYzaVpRsoXOU/EM="; npx:hasSignatureTarget this: . this: dct:created "2021-06-21T09:59:00.710+02:00"^^xsd:dateTime; dct:creator orcid:0000-0002-1468-3557; nt:wasCreatedFromProvenanceTemplate ; nt:wasCreatedFromPubinfoTemplate ; nt:wasCreatedFromTemplate . }